Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)

NCT ID: NCT01474772

Last Updated: 2021-01-28

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

217 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-10-31

Study Completion Date

2013-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The intent of this study is to treat subjects with painful Diabetic Peripheral Neuropathy (DPN) who also have pain on walking and to determine whether or not pregabalin demonstrates improvement relative to placebo on the following: reducing DPN pain, reducing pain on walking, and providing other benefits associated with daily activities and quality of life.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Peripheral Neuropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pregabain

Group Type EXPERIMENTAL

Pregabalin

Intervention Type DRUG

150-300 mg/day given in 3 divided doses as capsules

Placebo

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type OTHER

matching placebo capsules given in 3 divided doses

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pregabalin

150-300 mg/day given in 3 divided doses as capsules

Intervention Type DRUG

placebo

matching placebo capsules given in 3 divided doses

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lyrica

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men or women who are at least 18 years old.
* Diagnosis of painful diabetic peripheral neuropathy.
* Pain on walking.

Exclusion Criteria

* Inability to walk 50 feet on a flat surface.
* Pain on walking due to conditions other than diabetic peripheral neuropathy.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dedicated Clinical Research

Goodyear, Arizona, United States

Site Status

Arizona Research Center

Phoenix, Arizona, United States

Site Status

Neuro-Pain Medical Center

Fresno, California, United States

Site Status

HealthCare Partners Medical Group

Los Angeles, California, United States

Site Status

IDS Pharmacy

Los Angeles, California, United States

Site Status

University of Southern California

Los Angeles, California, United States

Site Status

PAB Clinical Research

Brandon, Florida, United States

Site Status

Pulmonary Associates of Brandon

Brandon, Florida, United States

Site Status

Innovative Research of West Florida, Inc.

Clearwater, Florida, United States

Site Status

The Office of Laszlo Jozef Mate, MD

North Palm Beach, Florida, United States

Site Status

Meridien Research

Tampa, Florida, United States

Site Status

Metabolic Research Institute, Inc.

West Palm Beach, Florida, United States

Site Status

Clinical Research of Central Florida

Winter Haven, Florida, United States

Site Status

Columbus Research Foundation

Columbus, Georgia, United States

Site Status

MediSphere Medical Research Center, LLC

Evansville, Indiana, United States

Site Status

Heartland Research Associates, LLC

Wichita, Kansas, United States

Site Status

Quality Clinical Research, Inc.

Omaha, Nebraska, United States

Site Status

Desert Endocrinology Clinical Research Center

Henderson, Nevada, United States

Site Status

Clinical Research Consortium

Las Vegas, Nevada, United States

Site Status

The Office of Dr. Stephen H. Miller, MD

Las Vegas, Nevada, United States

Site Status

The Medical Research Network, LLC

New York, New York, United States

Site Status

Neurology and Neuroscience Center of Ohio

Toledo, Ohio, United States

Site Status

Sooner Clinical Research

Oklahoma City, Oklahoma, United States

Site Status

The Office of Veronique Sebastian, MD

Oklahoma City, Oklahoma, United States

Site Status

Sunstone Medical Research, LLC

Medford, Oregon, United States

Site Status

Oregon Health and Science University - Comprehensive Pain Center

Portland, Oregon, United States

Site Status

Oregon Health and Science University - Department of Anesthesiology and Perioperative Medicine

Portland, Oregon, United States

Site Status

Blair Orthopedic Associates, Inc.

Altoona, Pennsylvania, United States

Site Status

Altoona Center for Clinical Research

Duncansville, Pennsylvania, United States

Site Status

Memorial Hospital of Rhode Island

Pawtucket, Rhode Island, United States

Site Status

Neurology and Pain Clinic, LLC

Orangeburg, South Carolina, United States

Site Status

Houston Neurocare

Houston, Texas, United States

Site Status

Centex Research, Inc.

Houston, Texas, United States

Site Status

Eastern Virginia Medical School

Norfolk, Virginia, United States

Site Status

Privatni specializovana ambulance pro neurologii a detskou neurologii

Brno-Bystrc, , Czechia

Site Status

Clintrial, s.r.o.

Prague, , Czechia

Site Status

Fakultni nemocnice v Motole

Prague, , Czechia

Site Status

Dr DR Lakha's Practice

Johannesburg, Gauteng, South Africa

Site Status

Dr Hemant Makan (Private Practice)

Lenasia, Gauteng, South Africa

Site Status

Randles Road Medical Centre

Durban, KwaZulu-Natal, South Africa

Site Status

Richards Bay Trial Centre

Richards Bay, , South Africa

Site Status

Forskningsmottagningen Gamla Sjukhuset i Falkoping

Falköping, , Sweden

Site Status

Center for Lakemedelsstudier

Malmo, , Sweden

Site Status

Citydiabetes

Stockholm, , Sweden

Site Status

Bragee Medect AB

Stockholm, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Czechia South Africa Sweden

References

Explore related publications, articles, or registry entries linked to this study.

Huffman C, Stacey BR, Tuchman M, Burbridge C, Li C, Parsons B, Pauer L, Scavone JM, Behar R, Yurkewicz L. Efficacy and Safety of Pregabalin in the Treatment of Patients With Painful Diabetic Peripheral Neuropathy and Pain on Walking. Clin J Pain. 2015 Nov;31(11):946-58. doi: 10.1097/AJP.0000000000000198.

Reference Type DERIVED
PMID: 25565583 (View on PubMed)

Related Links

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2011-003266-32

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

A0081269

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.